Tanfanercept (HBM9036) is a modified 19 kDa TNF receptor 1 fragment originally developed by HanAll Biopharma as an ophthalmic solution with good eye permeability, strong TNF-α neutralizing activity, high stability, and minor side effects. HBM licensed tanfanercept (HBM9036) from HanAll Biopharma and has the right to develop, manufacture and commercialize in Greater China (including Hong Kong, Macau and Taiwan).
Mechanism of Action
Tumor necrosis factor is a proinflammatory cytokine that plays a pivotal role in the pathogenesis of many inflammatory diseases. Tanfanercept is a molecularly engineered tumor necrosis factor receptor 1 fragment, produced by modification of the TNF-α binding region of the TNF-α receptor site. It is potent in binding and blocking TNF-α, resulting in suppressed inflammation after topical use.